Odronextamab Granted Priority Review for Rel/Ref FL, DLBCL
The FDA has accepted for priority review the biologics license application for odronextamab to treat adults with relapsed/refractory FL or DLBCL whose disease has progressed after at least 2 prior systemic therapies.